Rise Advisors’s Oruka Therapeutics ORKA Stock Holding History

Rise Advisors’s Portfolio ORKA Stock Details ORKA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-36	Closed	-$692	–	1502
2025 Q3	$692	Buy	+36	New	+$534	﹤0.01%	1330

Other funds holding ORKA

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Rise Advisors's ORKA Position: Q4 2025 in Review

Rise Advisors sold out of Oruka Therapeutics (ORKA) in Q4 2025, closing a stake of 36 shares — an estimated $692 sold.

Rise Advisors first reported a position in ORKA in Q3 2025 and held it in 1 quarter. The position peaked at $692 in Q3 2025. 143 funds tracked by Wall St. Rank hold ORKA as of Q4 2025.

Rise Advisors reported no remaining Oruka Therapeutics position as of Q4 2025 after selling out during the quarter.
Rise Advisors sold 36 Oruka Therapeutics shares in Q4 2025, an estimated $692.
Rise Advisors first reported a position in Oruka Therapeutics in Q3 2025 and held it in 1 quarter.
Rise Advisors's Oruka Therapeutics position peaked at $692 in Q3 2025.
143 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.